AstraZeneca PLC (NASDAQ:AZN) Announces Dividend of 1.60

AstraZeneca PLC (NASDAQ:AZN) announced a dividend on Tuesday, February 10th. Shareholders of record on Friday, February 20th will be given a dividend of 1.595 per share on Monday, March 23rd. The ex-dividend date is Friday, February 20th.

AstraZeneca has increased its dividend by an average of 0.0%per year over the last three years. AstraZeneca has a dividend payout ratio of 39.7% indicating that its dividend is sufficiently covered by earnings. Research analysts expect AstraZeneca to earn $5.00 per share next year, which means the company should continue to be able to cover its $2.02 annual dividend with an expected future payout ratio of 40.4%.

AstraZeneca Trading Up 3.0%

AstraZeneca stock traded up $5.60 during mid-day trading on Tuesday, hitting $193.61. The company’s stock had a trading volume of 1,585,837 shares, compared to its average volume of 4,269,538. The company has a 50 day moving average of $103.79 and a 200-day moving average of $89.45. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. The stock has a market cap of $300.27 billion, a PE ratio of 64.31, a P/E/G ratio of 1.59 and a beta of 0.34. AstraZeneca has a one year low of $122.48 and a one year high of $195.90.

More AstraZeneca News

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: AstraZeneca forecast mid-to-high single‑digit revenue growth and low‑double‑digit core EPS growth for 2026, giving the market confidence in ongoing top‑line and profit expansion driven by oncology and CV medicines. Read More.
• Positive Sentiment: Full‑year 2025 results showed revenue up ~8% (to $58.7B) with product sales rising ~9%, reinforcing that the company’s growth engine and pipeline delivery are translating into durable sales. This supports the longer‑term revenue target cited by management. Read More.
• Positive Sentiment: AstraZeneca announced a dividend of $1.595 per share (record Feb 20, pay Mar 23), which is supportive for income investors and can help underpin demand for the stock. (Company release)
• Positive Sentiment: Q4 revenue of about $15.5B came in slightly ahead at constant currency and was supported by cancer drug sales, which management highlighted as a growth driver — a near‑term sales beat that eased investor concerns. Read More.
• Neutral Sentiment: Analyst and media write‑ups provide deeper metric analysis and quarter snapshots; these detail where results met or lagged expectations and help investors parse one‑time items, FX effects and margin/cost dynamics. Read More. Read More.
• Negative Sentiment: Zacks notes AstraZeneca missed Q4 EPS and sales estimates, a weakness that could concern short‑term traders and suggests some near‑term margin or timing pressures despite the strong guidance. Read More.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.